Nuvama initiates coverage on Neuland Laboratories with a bull target of ₹17,700.
Peptide business is flagged as the long-term growth engine post-FY28.
Until then, Unit III expansion remains a critical near-term driver.
Growth acceleration is expected in H2 FY26, backed by a strong drug
pipeline.
The initiation signals renewed investor interest in specialty pharma.
Focus shifts to execution timelines and emerging peptide demand.
Analysts expect valuation re-rating if H2 capability ramps up as
projected.
Investors may watch regulatory approvals and capacity utilization as key ca
talysts.
Premium story for pharma allocations amid broader market optimism.
A neatly packaged long-term growth story for focused investors.